PSNL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Personalis Inc (PSNL) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown growth in clinical test volumes and revenue, its financial performance remains weak with significant net losses and declining gross margins. The technical indicators are mixed, and there are no strong trading signals or recent positive sentiment from options or insider trading. Given the investor's impatience and unwillingness to wait for optimal entry points, holding off on this investment for now is recommended.
The MACD is slightly positive but contracting, indicating weakening momentum. RSI is neutral at 44.123, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at 8.018, and resistance is at 9.298. Overall, the technical indicators are mixed and do not strongly suggest a buy.
The company has strengthened its partnership with Tempus, which could drive future growth in clinical test volumes.
The company anticipates a net loss of $105 million for 2026, and its gross margin dropped significantly by 59.56% YoY. Analysts have lowered price targets, and the market sentiment is neutral among hedge funds and insiders. Additionally, the stock is down 3.62% in the regular market and 2.10% in pre-market trading.
In Q4 2025, revenue increased by 3.24% YoY to $17.35 million, but net income remained negative at -$23.81 million, despite a 44.97% improvement YoY. EPS improved to -0.26, up 13.04% YoY, but gross margin dropped significantly to 10.95%, down 59.56% YoY. The company has $240 million in cash and short-term investments, providing some financial stability.
Analysts are mixed. Morgan Stanley lowered the price target to $10 from $11 and maintained an Equal Weight rating. Guggenheim raised the price target to $13 from $12 and maintained a Buy rating. The sentiment is cautious, reflecting concerns about higher operating expenses and net losses in the coming years.
